HER4 in Breast Cancer: Comparing Antibodies
Author Information
Author(s): Sian M Tovey, Barbara Dunne, Caroline J Witton, Timothy G Cooke, John MS Bartlett
Primary Institution: Glasgow University, UK
Hypothesis
The differences in reported outcomes related to HER4 expression in breast cancer may be dependent on the antibodies used for detection.
Conclusion
Different antibodies against HER4 reveal distinct staining patterns and may influence the interpretation of HER4's role in breast cancer prognosis.
Supporting Evidence
- The study involved 402 patients, providing a substantial sample size for analysis.
- Concordance between membrane staining patterns was high at 88.44%.
- Nuclear HER4 staining with the H4.77.16 antibody was associated with poorer overall survival.
Takeaway
This study looked at how different antibodies detect HER4 in breast cancer, finding that they show different patterns which could affect survival predictions.
Methodology
Immunohistochemistry was performed on tumors from 402 tamoxifen-treated estrogen receptor-positive patients using tissue microarray technology.
Potential Biases
Potential bias due to the use of different antibodies and their specificities in detecting HER4.
Limitations
The study is retrospective and relies on previously diagnosed patients, which may introduce selection bias.
Participant Demographics
Patients were tamoxifen-treated, estrogen receptor-positive women diagnosed with operable breast cancer between 1980 and 1999.
Statistical Information
P-Value
0.0124
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website